BDO Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

BDO Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-110	Closed	-$7K	–	1027
2022 Q3	$7K	Hold	110	–	–	﹤0.01%	772
2022 Q2	$7K	Hold	110	–	–	﹤0.01%	734
2022 Q1	$7K	Hold	110	–	–	﹤0.01%	777
2021 Q4	$8K	Hold	110	–	–	﹤0.01%	756
2021 Q3	$12K	Hold	110	–	–	﹤0.01%	697
2021 Q2	$18K	Sell	110 -35	-24%	-$4.26K	﹤0.01%	647
2021 Q1	$18K	Buy	+145	New	+$21.9K	﹤0.01%	628
2018 Q4	–	Sell	-10	Closed	–	–	562
2018 Q3	$0	Hold	10	–	–	﹤0.01%	624
2018 Q2	$1K	Buy	+10	New	+$570	﹤0.01%	615

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BDO Wealth Advisors's CRSP Position: Q4 2022 in Review

BDO Wealth Advisors sold out of CRISPR Therapeutics (CRSP) in Q4 2022, closing a stake of 110 shares — an estimated $7K sold.

BDO Wealth Advisors first reported a position in CRSP in Q2 2018 and held it in 9 quarters. The position peaked at $18K in Q2 2021. 398 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

BDO Wealth Advisors reported no remaining CRISPR Therapeutics position as of Q4 2022 after selling out during the quarter.
BDO Wealth Advisors sold 110 CRISPR Therapeutics shares in Q4 2022, an estimated $7K.
BDO Wealth Advisors first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 9 quarters.
BDO Wealth Advisors's CRISPR Therapeutics position peaked at $18K in Q2 2021.
398 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on BDO Wealth Advisors's 13F filing for Q4 2022, filed 27 Jan 2023.